Amplia (ASX: ATX) in the Spotlight: Bull, Bear, Base

Good morning,

Welcome to today’s edition of The Armchair Analyst, a 5-minute daily update on the ASX life-sciences sector.

Yesterday was a bloodbath.

So I did what I always do on days like that… 

Call the smartest people in the room.

The analysts.

(Mainly to console me.)

I have a few “regulars”, and yesterday it was Jacob Hoeing from Evolution Capital, to talk me through a few trading positions that were looking… shaky.

My dad always said a long-term portfolio is just a short-term trading portfolio gone wrong.

Halfway through the conversation, Jacob mentioned the Amplia (ASX: ATX) trading halt.

"Did you see Amplia?"

"Halt. Yeah. What's it for?"

"Results coming."

"What are we looking for? Give me a bull, bear, base."

"Well, pull up a chair."

And then Jacob gave me a detailed breakdown of the bull, bear, and base cases.

I stopped him halfway through.

"Jacob. The Armchair Army neeeeeeds to hear this."

So yesterday afternoon, Jacob put it all together for us.

It's important to set bull/bear/base case expectations BEFORE results drop. 

Because once they do, phrases like "pleased to announce" and "significant result" don't tell you much without a benchmark to hold them against.

Over to Jacob.

But first…

Algorae Pharmaceuticals (ASX: 1AI) appoints Mr. Waleed Elsayed (ex-Sandoz) as Head of Sales. (1AI)

🪑 It looks like 1AI is going all in on this generic product sales strategy. This is the third key hire in the space.

Paradigm Biopharmaceuticals (ASX: PAR) activates a clinical trial site in Hong Kong for its Phase 3 osteoarthritis study, nearing 50% recruitment. (PAR)

🪑 I wonder if they saw Racura’s 20% stock price rise yesterday off the back of their first patient dosed safely in Hong Kong and fastracked this announcement… 

Memphasys (ASX: MEM) reports uninterrupted operations in the Middle East despite regional conflict. (MEM)

🪑 Not sure I love this “nothing to see here” announcement by MEM. 

It just draws attention to the regional risk that has emerged in its go-to-market strategy. 

In a letter to shareholders, the Clinuvel (ASX: CUV) board has decided to continue the tenure of its CEO, Philippe Wolgen. (CUV)

🪑 This one is probably for the CUV superfans out there. 

But if CUV was going to do a big review only to come to the conclusion that “we’ve got the right guy”, why do it so publicly? Seems strange.

The FDA just announced that clinical trial sponsors can now submit data from organoids, organs-on-chips, and computational models. (Fierce Biotech) 

🪑 This is great news for an unlisted Australian company that I’ve been following closely, Cortical Labs, building “brain on a chip” technology.

AdAlta (ASX: 1AD) announces approval of a Canadian patent for its anti-fibrotic product. (1AD)

Hi, Jacob Hoeing here,

Healthcare analyst at Evolution Capital.

I’ve been covering Amplia Therapeutics (ASX: ATX) since July 2025, when the company reported an extraordinarily rare confirmed Complete Response in its Phase 2 clinical trial.

A result almost unheard of in pancreatic cancer. 

Amplia is a clinical-stage biotech developing narmafotinib, a drug designed to break down the protective barrier that pancreatic tumours build around themselves to resist chemotherapy. 

By dismantling these defences, narmafotinib aims to make standard chemotherapy work better.

The target indication is first-line metastatic pancreatic cancer (mPDAC): one of the deadliest cancers on the planet, with a 5-year survival rate of roughly 3%.

Yesterday, Amplia entered a trading halt ahead of its clinical trial readout.

Before I dive in, it’s important to know what we are looking for.

There are two key things to pay attention to:

mPFS is the time at which half the patients in a trial have experienced disease progression or died, showing how long the treatment keeps the cancer under control.

At the interim mark for Amplia’s trial, mPFS was 7.6 months and still maturing. 

The benchmark, set by the pivotal trial for the standard of care used today, is 5.5 months.

The trial has also delivered an Objective Response Rate (ORR) of 35% so far, meaning a third of patients saw their tumours shrink significantly, compared with 23% for the standard of care alone.

Amplia hasn’t yet published mOS numbers from its ACCENT trial. That is what the trading halt is for.

mOS is the time at which half the patients in a trial have died, showing how long patients lived after starting treatment.

Unlike PFS, which tracks disease control, OS answers the ultimate question: 

Does this drug help people live longer? 

The FDA considers Overall Survival the most definitive measure of whether a drug truly changes patient outcomes. 

In pancreatic cancer trials, there’s a fairly consistent relationship between PFS and OS. The OS number tends to come in at roughly 1.5-1.6x the PFS number.

When the standard-of-care chemo (gem/Abraxane) was tested alone, it yielded a mPFS of 5.5 months and an mOS of 8.5 months. That's a 1.55x conversion; 3.2 months added.

What I want to see from Amplia’s ACCENT trial is that adding narmafotinib to this chemotherapy yields a greater jump from PFS to OS than the chemotherapy achieves on its own. 

That’s the clearest sign that narmafotinib is genuinely contributing.

Interim results from Amplia’s ACCENT trial demonstrated a PFS of 7.6 months. 

Applying a 1.5-1.6x ratio gives us a ballpark mOS range of roughly 11.5 to 12.5 months. 

But, there is reason to think the final number could land toward the higher end.

9 patients were still on treatment as of October 2025, including some who had been on study for over 18 months. 

Those long-duration patients can pull the numbers up.

Not financial advice, but this is what I’m looking for.

A median survival of 13+ months would make Amplia’s narmafotinib the best-performing drug ever tested in first-line metastatic pancreatic cancer – beating both the existing standard (gem/Abraxane at 8.5 months) and the recently approved NALIRIFOX (11.1 months).

Why is this plausible? 

The interim data showed an unusually high number of patients responding deeply and remaining on treatment for a very long time. 

One patient had a confirmed Complete Response (all tumours disappeared), something that almost never happens in pancreatic cancer. 

Multiple patients were still on study past the 12-month mark. When you see that kind of “long tail” of durable responders, it tends to raise the median survival.

What it would mean: Amplia’s narmafotinib would have a clear claim to “best-in-class” status. This would dramatically strengthen Amplia’s hand in licensing negotiations with big pharma and would likely be the catalyst for a meaningful re-rating of the stock.

Based on the maths of the PFS-to-OS ratio from the interim results, this is the most likely outcome in my opinion. 

A survival number in this window would mean Amplia’s narmafotinib is competitive with or better than every existing treatment option for first-line pancreatic cancer.

Let’s put it into context.

The current standard of care delivers about 8.5 months of survival.

The best-approved alternative manages 11.1 months but has a more severe side-effect profile. 

If Amplia’s narmafotinib can match or beat those numbers while adding virtually no extra toxicity on top of chemotherapy, that’s a genuinely compelling clinical story.

What it would mean: The clinical thesis is validated. Amplia’s next trial, AMPLICITY, combining its drug with a different chemotherapy regimen, should be a well-supported program. The pathway to a big pharma partnership remains firmly on track.

This would be a disappointing result. 

A survival figure below 10.5 months would still beat the old gem/Abraxane benchmark of 8.5 months, but it would fall short of the recently approved NALIRIFOX (11.1 months).

That’s the new benchmark the market cares about.

What it would mean: The competitive story gets much harder to tell. Partnership discussions would likely be more difficult, and the market would probably react negatively. The investment case would still be alive, but Amplia would need strong data from its next AMPLICITY trial with its narmafotinib in combination with a different chemotherapy regimen. The burden of proof shifts significantly to the next trial.

I’ll have my full, detailed research on Amplia’s trial out when the results are published.

If you are interested. Feel free to email me [email protected], and I’ll make sure to send you a copy.

Thanks, Jacob, for putting that together for us.

If you do email Jacob for his Amplia report, make sure to say that The Armchair Analyst sent you!

See you all next week,

The Armchair Analyst.